查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乾粉吸入器全球市場-2022-2029
市場調查報告書
商品編碼
1146429

乾粉吸入器全球市場-2022-2029

Global Dry Powder Inhalers Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計 2021 年干粉吸入器市場規模將達到 9.37 億美元，預計在預測期間（2022-2029 年）將以 5.1% 的複合年增長率增長。

乾粉吸入器 (DPI) 以乾粉形式將藥物輸送到呼吸系統疾病患者的肺部。由於對在 P-MDI 中用作推進劑的氯氟烴 (CFC) 的環境問題日益關注，DPI 優於加壓計量吸入器。

市場動態

由於哮喘和慢性阻塞性肺病的發病率和患病率上升、技術進步和人口老齡化，對乾粉吸入器的需求不斷增加，推動了全球乾粉吸入器市場。

新藥技術進步推動市場增長

預計技術進步將在預測期內推動市場增長。傳統療法的局限性，例如起效慢和療效低，預計將推動新型靶向藥物的開發，從而推動市場。例如，賽諾菲在 2021 年 2 月與 Regeneron 合作宣布，itepekimab 與患有中度至重度慢性阻塞性肺病 (COPD) 的前吸煙者的急性中度至重度 COPD 惡化有關。已開始評估有效性和安全性。該試驗計劃於 2024 年 7 月結束。市場參與者正在採取各種策略，例如產品發布、開發、合作夥伴關係、收購和擴張，以增加他們的市場份額。例如，2020 年 7 月，龍沙在其位於俄勒岡州本德的現有工廠啟動了乾粉吸入器 (DPI) 藥物開發卓越中心，該公司將利用其粒子工程專業知識優化客戶配方。我們計劃幫助創建和評估。

根據世界衛生組織 (WHO) 2021 年情況說明書，COPD 是全球第三大死因，在 2019 年造成 323 萬人死亡。超過 80% 的死亡發生在低收入和中等收入國家 (LMIC)。此外，全球老齡化人口的增加也在推動市場增長。

哮喘治療的高成本預計將阻礙市場增長

哮喘吸入器的高成本可能會限制該行業的擴張。越來越多的患者接受呼吸手術並患有哮喘和慢性阻塞性肺病等慢性或呼吸系統疾病，因此需要創新的吸入器。然而，這些疾病設備的高成本可能會減少低收入國家對吸入器的採用。例如，根據 TalktoMira, Inc. 的數據，沒有保險的品牌哮喘吸入器的平均價格為 292.91 美元。

這些小工具和所需配件的高價可能會限制市場擴張。在擁有大量低收入人口的不發達國家，哮喘治療的高成本可能會限制市場增長。因此，中低收入國家可能難以引進如此昂貴的設備。因此，這些先進設備的高價格可能會在估計數年內抑制吸入器市場的增長。

COVID-19 影響分析

COVID-19 影響了全球藥品供應鏈，並影響了哮喘和 COPD 藥品市場。 Jose Luis Izquierdo 等人於 2021 年 3 月在《歐洲呼吸雜誌》上發表的一項研究發現，使用 COVID-19 的哮喘患者的鼻炎和濕疹等過敏相關因素較少。在需要住院的 COVID-19 患者中也觀察到這些合併症的高頻率。

此外，因 COVID-19 需要住院的患者使用的吸入性皮質類固醇 (ICS) 少於未住院患者（48.3% 對 61.5%）。接受生物製劑治療的患者在耳鼻喉科領域的嚴重程度和並發症增多，但這些患者因 COVID-19 住院的比例相對較低（0.23%）。因此，患有哮喘和 COVID-19 的患者年齡較大，並且與合併症相關的因素的風險增加。吸入性皮質類固醇 (ICS) 和生物製劑通常是安全的，並且可能與針對嚴重 COVID-19 感染的保護功效有關。患有慢性阻塞性肺病 (COPD) 的患者如果發展為 COVID-19，則其患重症肺炎的風險會增加且預後不良。這可能與潛在的肺儲備低或小氣道中 ACE-2 受體的表達增加有關。

行業分析

全球乾粉吸入器市場基於波特五力、監管分析、供應鏈分析和定價分析、報銷政策、技術進步、PEST 分析等各種行業因素。市場詳細信息提供了全面的分析。

細分分析

膠囊裝置細分市場有望在全球乾粉吸入器市場佔據最大份額

基於膠囊的設備細分市場受到以下因素的推動：在該細分市場提供多樣化產品的製造商數量增加、醫療保健專業人員和患者對這些設備的採用和偏好增加，以及普及率和哮喘發病率預計將主導全球乾粉吸入器市場。例如，2019 年 5 月，龍沙（Lonza）推出了 Capsugel Zephyr，一種經過優化的干粉吸入膠囊組合，可在膠囊/裝置和膠囊/製劑之間提供卓越的性能和兼容性。

哮喘患病率和發病率的顯著增加導致患者數量增加，從而導致對這些設備的需求增加。根據世界衛生組織 (WHO) 2021 年情況說明書，哮喘是一種主要的非傳染性疾病 (NCD)，影響兒童和成人。在全球範圍內，2019 年估計有 2.62 億人被感染，461,000 人死亡。對哮喘藥物研究的巨額投資以及併購等戰略聯盟是市場主要參與者採取的商業戰略。例如，2019 年 10 月，美國食品藥品監督管理局 (FDA) 批准了阿斯利康的哮喘藥物 Fasenra 用於自我給藥（一種預填充的一次性自動注射器）。

按地區分析

北美在全球乾粉吸入器市場中佔有最大份額

由於慢性阻塞性肺病和哮喘等疾病的發病率上升、人口老齡化、研發活動增加、主要市場參與者的存在等，北美在乾粉吸入器市場佔據主導地位。預計在預測期內將顯示出類似的趨勢.

在美國，成年女性的哮喘發病率高於成年男性。根據 2020 年疾病控制和預防中心的數據，美國約有 2500 萬美國人患有哮喘。這大約是 13 個美國人中的 1 個，其中 8% 是成年人，7% 是兒童。大約 2000 萬美國 18 歲以上的成年人患有哮喘。同樣，在加拿大，哮喘是一個主要的公共衛生問題。哮喘是一種終生呼吸道疾病，影響加拿大人的工作效率、生活質量、心理健康和心理健康。根據加拿大 2019 年哮喘調查年度報告，2019 年加拿大有超過 380 萬人患有哮喘。由於受哮喘影響的人數眾多，對治療目標疾病的藥物的需求正在增加，從而推動了該地區的增長。

競爭格局

由於該行業的主要市場參與者，乾粉吸入器市場競爭激烈。為全球市場增長做出貢獻的一些主要乾粉吸入器製造商包括 AstraZeneca PLC、Boehringer Ingelheim GmbH、Vectura Group plc、Otsuka Pharmaceutical Co. Ltd、Norton Healthcare、Respira Therapeutics, Inc、Chiesi、Cipla 等。領先的公司正在採用多種增長戰略，例如產品發布、收購和合作夥伴關係，這有助於全球市場的增長。例如，2021年3月，Glenmark Pharmaceuticals Ltd.在英國推出了生物等效版本的塞托溴銨乾粉吸入器（DPI），商品名為-Tiogiva，用於治療慢性阻塞性肺病（COPD）。

值得關注的重點公司

Vectura Group PLC

概述 Vectura Group PLC 開髮用於治療呼吸系統疾病的吸入療法。我們的主導產品用於治療哮喘和慢性阻塞性肺病。我們還開髮用於肺部疾病和非呼吸系統的產品。

Vectura 的主要產品有 10 種吸入式和 11 種非吸入式產品，並由全球擁有版稅收入來源的合作夥伴銷售。我有一個產品組合。

產品組合 Gyrohaler：一種多桶乾粉吸入器，旨在將局部作用的藥物輸送到肺部。

關鍵發展：2021 年，Vectura 將擴大其在英國奇彭納姆工廠的干粉吸入器開發和製造能力。

本報告提供對全球乾粉吸入器市場約 45 多個市場數據表、40 多個圖表和 180 頁的訪問權限。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品類型劃分的市場細分
  • 按適應症類型劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
  • 促進因素
    • 呼吸設備的普及率提高
    • 空氣污染水平不斷上升，尤其是在發展中國家
  • 抑制因素
    • 劑量不均勻，設備成本高
  • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 法律法規分析
  • 定價分析
  • 技術進步
  • 保險報銷分析
  • 未滿足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 膠囊裝置
  • 泡罩式設備
  • 儲液器/筒式裝置
  • 其他

第 8 章療效

  • 支氣管炎
  • 慢性阻塞性肺病 (COPD)
  • 哮喘
  • 其他

第 9 章按銷售渠道

  • 醫院藥房
  • 在線藥店
  • 零售藥房
  • 藥店

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 關鍵戰略分析
  • 技術組合對比分析
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • Vectura Group plc
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • GlaxoSmithKline plc
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Otsuka Pharmaceutical Co. Ltd
  • Norton Healthcare
  • Respira Therapeutics, Inc
  • Boehringer Ingelheim
  • Chiesi
  • Cipla

第 13 章全球乾粉吸入器市場-DataM

簡介目錄
Product Code: DMMD1827

Market Overview

Dry Powder Inhalers Market size was valued US$937 million in 2021 and is growing at a CAGR of 5.1% during the forecast period (2022-2029).

Dry powder inhalers (DPI) deliver drugs in the form of dry powder to the lungs of patients suffering from respiratory disorders. These are preferred over pressurized metered dose inhalers due to rising environmental concerns regarding chloro-flouro carbon (CFC) used as a propellant in P-MDIs.

Market Dynamics

The global dry powder inhalers market is due to an increasing demand of dry powder inhalers owing to the rise in incidence and prevalence of asthma and COPD, technological advancements, and a growing geriatric population.

Technological advancements in novel drugs drives the growth of the market

Technological advancements are anticipated to drive the growth of the market in the forecast period. Limitations of traditional treatments, such as the late onset of action and low efficacy, are projected to encourage the development of novel targeted drugs, thereby driving the market. For instance, in February 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a Phase III clinical trial to assess the efficacy and safety of itepekimab on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial is expected to be completed in July 2024. The market players are adopting various strategies such as product launches, developments, collaborations, acquisitions, and expansions to increase their market shares. For instance, In July 2020, Lonza launched a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its exsiting facility in Bend, OR, in which the company will use its expertise in particle engineering to help customers to create and evaluate formulations.

According to the World Health Organization (WHO) 2021 factsheet, COPD is the third-leading cause of death worldwide, causing 3.23 million deaths in 2019. Over 80% of these deaths occurred in low- and middle-income countries (LMIC). Moreover, the increasing geriatric population globally is boosting the market growth.

The high cost of asthma treatment is expected to hamper the market growth

The expensive cost of asthma inhalers could limit industry expansion. A growing proportion of patients undergoing respiratory operations need innovative inhalers because they have chronic and respiratory disorders like asthma and COPD. However, the adoption rate of inhalers may decline throughout low-income countries as a result of the high cost of these devices for these disorders. For instance, according to the TalktoMira, Inc, the average price of one brand-name asthma inhaler is $292.91 without insurance.

The expensive price of these gadgets and necessary accessories could limit market expansion. Market growth in underdeveloped nations with relatively low-income levels may be constrained because to the high costs involved with asthma procedures. As a result, it might be challenging for middle-income and low-income countries to adopt such expensive devices. Therefore, the high price of these advanced devices could restrain the expansion of the inhalers market over the estimated year.

COVID-19 Impact Analysis

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the Asthma and COPD drug market. According to a research study by Jose Luis Izquierdo et al., published in the European Respiratory Journal, March 2021, allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19. There was a high prevalence of these comorbidities observed in patients with COVID-19 who required hospital admission.

Furthermore, the use of inhaled corticosteroids (ICS) was lower in patients who required hospitalization due to COVID-19 compared to non-hospitalized patients (48.3% versus 61.5%). Although patients treated with biologics showed increased severity and more comorbidities at the ear, nose, and throat levels, COVID-19-related hospitalizations in these patients were relatively low (0.23%). Thus, patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. Inhaled corticosteroids (ICS) and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection. Chronic obstructive pulmonary disease (COPD) patients have an increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptors in small airways.

Industry Analysis

The global dry powder inhalers market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis and pricing analysis, reimbursement policies, technological advancements, PEST analysis.

Segment Analysis

The capsule based devices segment is expected to hold the largest market share in global dry powder inhalers market

The capsule based devices segment is expected to dominate the global dry powder inhalers market, owing to increase in number of manufacturers offering diverse products in the segment and rise in adoption and preference of health care providers and patients for these devices and also increase in prevalence and incidence of asthma. For instance, In May 2019, Capsugel Zephyr is launched by Lonza, a dry-powder inhalation capsule portfolio that is optimized to provide superior performance and compatibility between the capsule/device and capsule/formulation.

The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these devices. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million people in 2019 and caused 461,000 deaths. Enormous investments in the study of asthma drugs accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market. For instance, in October 2019, the US Food and Drug Administration (FDA) approved the self-administration of AstraZeneca's asthma drug Fasenra, a pre-filled, single-use auto-injector.

Geographical Analysis

North America region holds the largest market share in the global dry powder inhalers market

North America dominates the market for dry powder inhalers and is expected to show a similar trend over the forecast period, owing to the rising incidence of diseases such as COPD and asthma, the aging population, increasing research and development activities, and the presence of key market players.

In the United States, asthma is more common in adult women than adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million US adults aged 18 years and over have asthma. Similarly, asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological well-being of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per Canada's 2019 annual asthma survey report. The high number of patients affected by asthma increases the demand for drugs for the treatment of the target disease, thereby boosting the growth of this region.

Competitive Landscape

The dry powder inhalers market is highly competitive, owing to big market players in the industry. The key dry powder inhalers players which are contributing to the growth of the global market include AstraZeneca PLC, Boehringer Ingelheim GmbH, Vectura Group plc, Otsuka Pharmaceutical Co. Ltd, Norton Healthcare, Respira Therapeutics, Inc, Chiesi, Cipla and among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in March 2021, Glenmark Pharmaceuticals Ltd, launched a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

Key Companies to Watch

Vectura Group PLC:

Overview: Vectura Group PLC develops inhaled therapies for the treatment of respiratory diseases. The Company's main products are used to treat asthma and chronic obstructive pulmonary disease. Vectura also develops products for lung pathologies and non-respiratory.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.

Product Portfolio: Gyrohaler: is a multi-unit dose dry powder inhaler designed to deliver locally acting drugs to the lungs.

Key Developments: In 2021, Vectura expands dry powder inhaler development and manufacturing capabilities at its facility in chippenham, U.K.

The global dry powder inhalers market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Indication Type
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Increasing Prevalence of Respiratory Devices
    • 4.2.2. Increasing Air Pollution Levels Especially in Developing Countries
  • 4.3. Restraints
    • 4.3.1. Inaccuracy In Dose Uniformity and High Cost of Devices
  • 4.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porters Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Technological Advancements
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
  • 7.3. Market Attractiveness Index, by Product Type
  • 7.4. Capsule Based Device *
    • 7.4.1. Introduction
    • 7.4.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.5. Blister Based Devices
  • 7.6. Reservoir/Cartridge Based Devices
  • 7.7. Others

8. By Indication Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 8.1.2. Market Attractiveness Index, by Indication Type
  • 8.2. Bronchitis*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Chronic Obstructive Pulmonary Diseases (Copd)
  • 8.4. Asthma
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Distribution Channel
  • 9.3. Market Attractiveness Index, by Distribution Channel
  • 9.4. Hospital Pharmacies *
    • 9.4.1. Introduction
  • 9.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.6. Online Pharmacies
  • 9.7. Retail Pharmacies
  • 9.8. Drug Stores

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Countries
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Indication Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Countries
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Distribution Channel
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Key Strategy Analysis
  • 11.3. Comparative Technology Portfolio Analysis
  • 11.4. Market Positioning/Share Analysis
  • 11.5. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Vectura Group plc *
    • 12.1.1. Company overview
    • 12.1.2. Product portfolio and description
    • 12.1.3. Key highlights
    • 12.1.4. Financial overview
  • 12.2. GlaxoSmithKline plc
  • 12.3. AstraZeneca
  • 12.4. Boehringer Ingelheim GmbH
  • 12.5. Otsuka Pharmaceutical Co. Ltd
  • 12.6. Norton Healthcare
  • 12.7. Respira Therapeutics, Inc
  • 12.8. Boehringer Ingelheim
  • 12.9. Chiesi
  • 12.10. Cipla

LIST NOT EXHAUSTIVE

13. Global Dry Powder Inhalers Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us